TOKYO -- SoftBank Group-backed U.S. biotech startup Relay Therapeutics gained 75% on its trading debut on Nasdaq, raising hopes for a recovery in the performance of Softbank's $100 billion Vision Fund.
Shares in Relay, which is developing drugs for cancer treatment, closed at $35.05 on Thursday compared to its offering price of $20, giving the company a market capitalization of about $3 billion. It raised $400 million from an initial public offering.
%2520%E3%82%BD%E3%83%95%E3%83%88%E3%83%90%E3%83%B3%E3%82%AF%E3%82%B0%E3%83%AB%E3%83%BC%E3%83%97%E3%80%80%E6%B1%BA%E7%AE%97%E7%99%BA%E8%A1%A820200629174437908_Data.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
